浏览全部资源
扫码关注微信
1.黄石市中心医院/湖北理工学院 附属医院,湖北 黄石 435200
2.肾脏疾病发生与干预湖北省重点实验室,湖北 黄石 435200
董克臣,硕士,副主任医师,从事头颈肿瘤及淋巴瘤的基础与临床研究,E-mail:dkchappy@sina.com
费新雄,主任医师,从事淋巴瘤的基础研究和转化研究,E-mail:2201414041@qq.com
纸质出版日期:2024-09-05,
网络出版日期:2024-06-20,
收稿日期:2024-02-09,
扫 描 看 全 文
董克臣,梁毅,李松等.西红花总苷片结合微量泵输注多柔比星防治弥漫性大B细胞淋巴瘤患者急性心脏损伤的临床疗效[J].中国实验方剂学杂志,2024,30(17):131-137.
DONG Kechen,LIANG Yi,LI Song,et al.Clinical Observation on Crocin Tablets Combined with Micropump Infusion of Doxorubicin for Prevention of Acute Cardiotoxicity in Patients with Diffuse Large B-cell Lymphoma[J].Chinese Journal of Experimental Traditional Medical Formulae,2024,30(17):131-137.
董克臣,梁毅,李松等.西红花总苷片结合微量泵输注多柔比星防治弥漫性大B细胞淋巴瘤患者急性心脏损伤的临床疗效[J].中国实验方剂学杂志,2024,30(17):131-137. DOI: 10.13422/j.cnki.syfjx.20241995.
DONG Kechen,LIANG Yi,LI Song,et al.Clinical Observation on Crocin Tablets Combined with Micropump Infusion of Doxorubicin for Prevention of Acute Cardiotoxicity in Patients with Diffuse Large B-cell Lymphoma[J].Chinese Journal of Experimental Traditional Medical Formulae,2024,30(17):131-137. DOI: 10.13422/j.cnki.syfjx.20241995.
目的
2
观察西红花总苷片结合微量泵输注多柔比星防治弥漫性大B细胞淋巴瘤(DLBCL)患者急性心脏损伤的临床效果,并探讨相关机制。
方法
2
选择2022年10月至2023年10月从黄石市中心医院收集的DLBCL患者病例,将符合纳入标准的92例受试者按照1∶1比例随机分配至对照组和观察组,每组各46例。对照组行常规静脉输注多柔比星,观察组接受西红花总苷片联合微量泵输注多柔比星。比较两组异常心电图发生情况、化疗前后心肌损伤标志物、心功能指标、氧化应激、炎性因子和血液流变学指标变化。
结果
2
观察组异常心电图发生率(23.91%,11/46)显著低于对照组(54.35%,25/46),差异有统计学意义(
χ
2
=8.944,
P
<
0.01)。化疗后第8天,观察组肌酸激酶同工酶(CK-MB)和心肌肌钙蛋白I(cTnI)异常率明显低于对照组,差异有统计学意义(
χ
2
=4.423、4.857,均
P
<
0.05)。与对照组治疗后比较,观察组N末端B型脑钠肽前体(NT-proBNP)水平显著下降,左室射血分数(LVEF)显著升高(
P
<
0.01);观察组总抗氧化能力(T-AOC)和超氧化物歧化酶(SOD)水平显著升高(
P
<
0.01),观察组白细胞介素-6(IL-6)和肿瘤坏死因子-
α
(TNF-
α
)水平显著下降,差异有统计学意义(
P
<
0.01);观察组全血低切黏度(LWBV)、全血高切黏度(HWBV)、血浆黏度(PV)和纤维蛋白原(FIB)水平均显著下降(
P
<
0.01)。
结论
2
西红花总苷片结合微量泵输注多柔比星能够有效减轻DLBCL患者急性心脏损伤,降低异常心电图发生率,具有保护心肌细胞和改善心功能作用。其机制可能与抗氧化、抗炎及改善血液流学等相关。
Objective
2
To observe the clinical effect of crocin tablets (CRO) combined with micropump infusion of doxorubicin in the prevention of acute cardiotoxicity in the patients with diffuse large B-cell lymphoma (DLBCL) and explore the related mechanism.
Method
2
The patients with DLBCL treated in the Huangshi Central Hospital from October 2022 to October 2023 were selected, and 92 patients who met the inclusion criteria were randomly assigned to a control group and an observation group at a ratio of 1∶1, with 46 patients in each group. The control group underwent conventional intravenous infusion of doxorubicin, and the observation group received CRO combined with micropump infusion of doxorubicin. The changes of abnormal ECG, myocardial injury markers, cardiac function indicators, oxidative stress, inflammatory mediators, and hemorheological indexes before and after chemotherapy were compared between the two groups.
Result
2
The incidence of abnormal ECG in the observation group was 23.91% (11/46), which was lower than that (54.35%, 25/46) in the control group (
χ
2
=8.944,
P
<
0.01). On day 8 after chemotherapy, the abnormal rates of creatine kinase-MB (CK-MB) and cardiac troponin I (cTnI) in the observation group were lower than those in the control group (
χ
2
=4.423, 4.857, both
P
<
0.05). Compared with the control group after chemotherapy, the observation group showed lowered level of N-terminal pro-B-type natriuretic peptide, elevated left ventricular ejection fraction and levels of total antioxidant capacity and superoxide dismutase (
P
<
0.01), declined levels of interleukin-6 and tumor necrosis factor-
α
(
P
<
0.01), and decreased low whole blood viscosity, high whole blood viscosity, plasma viscosity, and fibrinogen (
P
<
0.01).
Conclusion
2
CRO combined with micropump infusion of doxorubicin can mitigate acute cardiotoxicity, reduce the incidence of abnormal ECG, protect cardiomyocytes, and improve the cardiac function by exerting the antioxidant and anti-inflammatory effects and improving blood flow.
弥漫性大B细胞淋巴瘤多柔比星心脏毒性西红花总苷片疗效机制
diffuse large B-cell lymphomadoxorubicincardiotoxicitycrocin tabletstherapeutic effectmechanism
SONG Y,TILLY H,RAI S,et al.Polatuzumab vedotin in previously untreated DLBCL:An Asia subpopulation analysis from the phase 3 POLARIX trial[J].Blood,2023,141(16):1971-1981.
LANG R,GILL M J.Diffuse Large B-cell lymphoma[J].N Engl J Med,2021,384(23):2261-2262.
ZAORSKY N G,CHURILLA T M,EGLESTON B L,et al.Causes of death among cancer patients[J].Ann Oncol,2017,28(2):400-407.
魏玥,曲华,彭煜暄,等.蒽环类药物心脏毒性的监测与防治研究进展[J].中国实用内科杂志,2023,43(2):159-164.
中国抗癌协会肿瘤临床化疗专业委员会,中国抗癌协会淋巴瘤专业委员会.中国蒽环类药物治疗淋巴瘤专家共识[J].癌症,2021,40(11):465-474.
朱俊峰,伊晓娇,钟里科,等.中药抗阿霉素心脏毒性的中医理论及其药理作用研究进展[J].中华中医药杂志,2022,37(8):4592-4598.
QIU Y,JIANG P,HUANG Y.Anthracycline-induced cardiotoxicity:Mechanisms,monitoring,and prevention[J].Front Cardiovasc Med,2023,10:1242596.
孔一帆,卫晓红,张迪,等.基于CiteSpace对中医药治疗蒽环类所致心脏毒性的可视化分析[J].中草药,2023,54(19):6400-6412.
李艳阳,王云姣,吕仕超.中药注射液防治抗肿瘤药物心脏毒性的效应和机制[J].中国临床药理学与治疗学,2023,28(5):572-577.
牛少辉,熊海燕,栗媛,等.西红花苷通过调控SIRT1/Nrf2通路对心肌缺血再灌注大鼠的保护作用[J].中成药,2023,45(4):1323-1327.
张东梅,武卫党,徐晓辉,等.西红花苷通过恢复线粒体功能改善大鼠心肌缺血/再灌注损伤的效果[J].临床医学研究与实践,2021,6(36):14-17.
黄建成,郭世超,刘璞娟,等.西红花苷对大鼠缺血缺氧心肌损伤的保护作用及其机制[J].吉林大学学报:医学版,2021,47(1):102-109.
MOTLAGH P E,NOVIN A G,GHAHARI F,et al.Evaluation of the effect of crocin on doxorubicin-induced cardiotoxicity[J].Adv Exp Med Biol,2021,1328:143-153.
苏鑫.西红花苷防治乳腺癌蒽环类化疗药物诱发的左室舒张功能下降的临床研究和机制研究[D].北京:中国中医科学院,2023.
XU P ,SUN C ,CAO X, et al.Immune characteristics of chinese diffuse large B-cell lymphoma patients: Implications for cancer immunotherapies[J].EBioMedicine,2018,33:94-104.
姜金龙,计成阜,何广胜,等.生脉注射液结合持续静脉缓慢滴注蒽环类药物降低早期心脏毒性发生风险的临床观察[J].现代肿瘤医学,2021,29(3):499-502.
DEMPKE W,ZIELINSKI R,WINKLER C,et al.Anthracycline-induced cardiotoxicity - Are we about to clear this hurdle?[J].Eur J Cancer,2023,185:94-104.
CAI F,LUIS M,LIN X,et al.Anthracycline-induced cardiotoxicity in the chemotherapy treatment of breast cancer:Preventive strategies and treatment[J].Mol Clin Oncol,2019,11(1):15-23.
CARDINALE D,IACOPO F,CIPOLLA C M.Cardiotoxicity of anthracyclines[J].Front Cardiovasc Med,2020,7:26.
李艳阳,王云姣,韩德军,等.基于数据挖掘的中医药治疗抗肿瘤药物心脏毒性用药规律研究[J].中国中医基础医学杂志,2022,28(1):138-141.
李艳阳,孙海燕,姜战胜,等.中医药防治抗肿瘤药物心脏毒性的研究[J].中国中医基础医学杂志,2018,24(11):1602-1606.
童鑫,洪吟秋,张涛,等.西红花柱头化学成分及其抗炎活性[J].中成药,2022,44(4):1142-1147.
张业昊,从伟红,刘建勋.西红花苷的药理作用研究进展[J].中药药理与临床,2015,31(2):124-127.
韩笑,王攀,刘建勋,等.西红花酸对阿霉素诱导大鼠心肌细胞损伤的影响[J].中国中医药信息杂志,2021,28(10):64-69.
ZHANG H,LIN J,SHEN Y,et al.Protective effect of crocin on immune checkpoint inhibitors-related myocarditis through inhibiting NLRP3 mediated pyroptosis in cardiomyocytes via NF-κB pathway[J].J Inflamm Res,2022,15:1653-1666.
张彦池.西红花苷防治乳腺癌蒽环类化疗患者心脏毒性的临床观察[D].张家口:河北北方学院,2022.
陈樟荥.西红花总苷片预防乳腺癌蒽环类化疗药物心脏毒性的临床研究[D].济南:山东中医药大学,2022.
毕磊,曹丹阳,郭智.恶性血液病患者蒽环类药物化疗期间心电图异常分析[J].中国循证心血管医学杂志,2017,9(11):1354-1356.
王鑫,李晓琪,迟伟群.化疗导致的心脏毒性生物标志物研究进展[J].国际检验医学杂志,2022,43(16):2037-2042.
HILL L,DELGADO B,LAMBRINOU E,et al.Risk and management of patients with cancer and heart disease[J].Cardiol Ther,2023,12(2):227-241.
黄万钟,周锋,夏瑜,等.N-端脑钠肽前体联合肌钙蛋白对化疗所致心脏毒性的早期诊断意义[J].中国临床药理学杂志,2018,34(22):2594-2597.
ATTANASIO U,PIROZZI F,POTO R,et al.Oxidative stress in anticancer therapies-related cardiac dysfunction[J].Free Radic Biol Med,2021,169:410-415.
DING Z,LIU S,WANG X,et al.Oxidant stress in mitochondrial DNA damage,autophagy and inflammation in atherosclerosis[J].Sci Rep,2013,3(1):1077.
李晓琪,王鑫,姜廷军,等.蒽环类药物引发心脏毒性的相关机制研究进展[J].医学综述,2022,28(12):2332-2337.
0
浏览量
5
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构